ARA-290 (cibinetide) is an 11-amino acid non-erythropoietic peptide derived from erythropoietin's helix-B domain. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production.
Quickstart Highlights
- Dosage: 2-4mg
- Frequency: Daily
- Administration: Subcutaneous
- Cycle length: 4-12 weeks
Dosing Plan
| Weeks | Dose | Units |
|---|---|---|
| Week 1 | 2mg once daily | 25 units (0.25mL) |
| Weeks 2–4 | 4mg once daily | 50 units (0.50mL) |
| Weeks 5–12 | 4mg once daily | 50 units (0.50mL) |
How to mix
Add 2.0mL bacteriostatic water per 16mg vial → 8mg/mL concentration
- Draw 2.0mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall.
- Gently swirl until dissolved.
- Label with date and refrigerate at 2–8°C; use within 28 days.
Syringe Math Reference
- 16mg vial with 2mL BAC water = 8 mg/mL
- 1 unit = 0.01mL = 80mcg
- 2mg dose = 25 units (0.25mL)
- 4mg dose = 50 units (0.50mL)
What you'll need
ARA-290 Vials (16mg)
- 4 weeks 1 vial
- 8 weeks 2 vials
- 12 weeks 3 vials
Insulin Syringes (U-100)
- 4 weeks 30 syringes
- 12 weeks 90 syringes
Bacteriostatic Water (10mL)
- 12 weeks 1 bottle
Alcohol Swabs
- 12 weeks 1 × 100-count box
How This Works
ARA-290 is derived from the helix-B surface of erythropoietin but lacks erythropoietic activity. It selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βcR), which is expressed on cells involved in tissue protection and repair. This activation promotes anti-inflammatory responses, cytoprotection, and tissue repair without affecting red blood cell production.
Mechanism of Action
How ARA-290 Works in Your Body
Peptide Administered
Enters the bloodstream via injection
Receptor Binding
Finds and activates its target receptor
Signal Cascade
Triggers a chain of cellular responses
Biological Effect
The body produces the desired outcome
Benefits & Side Effects
Potential Benefits
- Improvement in neuropathic symptoms
- Reduced small fiber neuropathy
- Anti-inflammatory tissue protection
- Nerve regeneration support
- Pain reduction in neuropathy
Potential Side Effects
- Generally well tolerated in clinical trials
- Injection site reactions (mild)
- Headache (occasional)
- GI upset (rare)
How to store it
- Lyophilized: Refrigerate at 2–8°C or freeze at −20°C.
- Reconstituted: Refrigerate and use within 28 days.
Good to know
- Clinical trials show benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy.
- Does not stimulate erythropoiesis (red blood cell production).
- Activates the innate repair receptor for tissue-protective effects.
- Well-studied in Phase 2/3 clinical trials.
Community Insights
Summarised from 3 sourcesCommunity discussions on Reddit suggest that ARA-290, also known as Cibinetide, is being explored for its potential in nerve regeneration and its role in an environment conducive to muscle and nerve regrowth. Users have noted a lack of negative effects in their experiences. The peptide has been discussed in combination with other compounds for various therapeutic goals. While direct user experiences with ARA-290 for specific conditions like fibromyalgia are not detailed in the provided snippets, its potential synergy with other peptides and hormones for regenerative purposes is a recurring theme. The discussions highlight an interest in its therapeutic applications, particularly in the context of neurological health and tissue repair.
Common Dosages Reported
- Phase I trials used 8 mg per day as the highest dose
- Phase II trials used 8 mg as the effective dose
Stacking Suggestions
- Testosterone
- Growth Hormone
What people are saying
No negative effects noticed.
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Inquiry Regarding ARA-290 Experience
A user inquired about others' experiences with the peptide ARA-290 (Cibinetide) within a biohacking community. However, the provided source does not contain specific personal usage reports or results for this peptide, focus mostly on requesting information from others.
Protocol for Vagus Nerve Neuropathy and Dysautonomia
A user shared a protocol for treating vagus nerve neuropathy and dysautonomia using ARA-290 at a dosage of 4mg daily for 28 days. They noted that tracking heart rate variability (HRV) would provide objective data on the efficacy of the treatment, mirroring clinical trial standards.
No discussion yet — be the first.
No notes yet — be the first.